Bioanalytics - Biomolecular - Drug Quantification

(M0930-09-50) Robustness Testing of an Assay for Flow Cytometric CAR Persistence Determination

(M1130-09-51) Development and Validation of an LC-MS/MS Method for Determination of Difelikefalin in Human Plasma

(T1230-09-49) Validation of an MFLC-MS/MS Assay for the Quantitative Analysis of a Novel Peptide, AT-01, Extracted from K₂EDTA Plasma

(T1230-09-51) Direct Monitoring of DNA Plasmid Concentration and the Extent of Plasmid-Liposome Complexation Using 2^nd Derivative Fiber-Optic UV Spectroscopy

(T1230-09-52) A Sensitive Solution for Quantification of Anti-sense Oligonucleotides (ASOs) in Rat Plasma Using High-Resolution Mass Spectrometry

(T1230-09-53) Novel LC-MS/MS Analyses for Glucagon-Like Peptide-1 (GLP-1) Analogs, Liraglutide, Lixisenatide, and Semaglutide, and Pharmacokinetic Evaluation in Rats

(T1430-09-52) Hybrid-LC-MS/MS Method for Simultaneous Quantification of Two COVID-19 Biotherapeutic Monoclonal Antibodies in Human Serum

(T1530-09-50) Pharmacokinetics and Brain Distribution of the Therapeutic Peptide Semaglutide by a Novel Liquid Chromatography-Tandem Mass Spectrometry

(T1530-09-51) Novel HILIC-LC-MS Method for Quantification of Ketone Bodies (beta-hydroxybutyrate and acetoacetate) in Human Plasma

(T1530-09-52) Impact of Autosampler Design on Carryover Performance During Method Migration

(T1530-09-53) Quantitating the Concentration of DNA Plasmid Using 2^nd Derivative Fiber-Optic UV Spectroscopy and Intercalating Dye

(T1530-09-54) Sensitive Bioanalysis of Anti-sense Oligonucleotides through Mitigation of Non-specific Binding and Improved LC-MS/MS Performance